New medication shows promise in treating common skin disease

July 9, 2014

An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis, according to a study published July 9 in the New England Journal of Medicine. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead author Lisa A. Beck, M.D., professor of Dermatology and Medicine at the University of Rochester Medical Center.

The drug, dupilumab, blocks the action of two proteins involved in inflammation, interleukin-4 and interleukin-13, which play a key role in (AD). AD is a common with troubling signs that include severely dry , red lesions that may crust or ooze, skin thickening, and symptoms of intense itching that may lead to skin wounds, infections and sleep disturbance.

Moderate-to-severe AD is a more chronic version of the disease that typically has more systemic features and is seen in up to 3 percent of adults with the disease. AD can impact a person's ability to lead a full and active life. In addition, people with AD are more likely to have asthma and other allergic disorders such as hay fever. Current treatments for AD include topical and oral steroids as well as phototherapy, but their effectiveness is limited or the side effects associated with their chronic use are significant.

"We are encouraged by the consistent findings across these studies, which show that patients treated with dupilumab had a marked improvement in disease activity and itch," Beck said. "At this point, dupilumab appears to be remarkably effective for adults with severe AD, although larger studies are needed to confirm its safety and efficacy."

Dupilumab is administered as a skin injection, and has shown promise in both Phase I and Phase II studies. Participants in a 12-week Phase II study showed a 74 percent reduction in the Eczema Area Severity Index, a tool used to measure the severity of a patient's condition, compared to only 23 percent in the placebo group. The majority of patients in the group receiving dupilumab experienced significant reductions in itch.

The study's findings set the stage for Phase III clinical trials of dupilumab, to confirm its effectiveness, monitor side effects, and compare it to commonly used treatments.

Dupilumab is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc., and Sanofi.

Explore further: Monoclonal antibody appears effective and safe in asthma Phase IIa trial

Related Stories

Monoclonal antibody appears effective and safe in asthma Phase IIa trial

May 21, 2013
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.

Study suggests symptoms of childhood eczema persist, likely a lifelong illness

April 2, 2014
Children diagnosed with atopic dermatitis (AD or eczema) may have symptoms persist into their 20s, and the condition is likely to be a lifelong illness marked by waxing and waning skin problems.

First genetic mutations linked to atopic dermatitis identified in African-American children

November 11, 2013
Two specific genetic variations in people of African descent are responsible for persistent atopic dermatitis (AD), an itchy, inflammatory form of the skin disorder eczema. A new report by researchers in the Perelman School ...

Large-scale Japanese genomics project finds eight new loci linked to atopic dermatitis

February 22, 2013
Around one in ten Japanese school children suffer from a debilitating form of eczema known as atopic dermatitis (AD). Despite clear signs that the condition is heritable, the genetic origins of the disease have remained elusive. ...

Sequential oral, topical tacrolimus benefits dermatitis

September 20, 2012
(HealthDay)—Sequential therapy with oral tacrolimus and topical tacrolimus may be an effective treatment for severe atopic dermatitis (AD), according to a pilot study published in the October issue of the Journal of the ...

Wet wraps cut need for drugs in kids with eczema

July 8, 2014
The number of children with atopic dermatitis, often referred to as eczema, is on the rise. Some estimate that one in five children in the U.S. now suffers from the painful, itchy skin condition. In an effort to control their ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.